Recently, the company underwent a stock split, where the face value of each share was reduced from Rs 10 to Rs 2. The record date for this stock split was March 17, 2023. Prior to the stock split, the company also issued a bonus in the ratio of 82:32, with a record date of June 02, 2022.

The company offers a diverse portfolio of products and services, including APIs, generics, branded generics, biosimilars and over-the-counter medications. With a history of scientific advancements and industry-first achievements, the company remains committed to investing in future business opportunities.

Shares of this company have gained over 13 per cent in just three sessions of June.

The price band of the issue has been fixed at Rs 270 to Rs 285 per equity share. The issue size is Rs 607 crore at a higher price band.

In Q4FY23, the company reported a 124 per cent increase in net profits YoY.  

Both companies are public sector undertakings, with the majority ownership held by the President of India (NTPC Ltd holds a stake of 51.10 per cent, while Indian Oil Corporation Ltd holds a stake of 51.50 per cent).

On Monday, most Asian stocks extended a global surge on expectations that the Fed will pause rate hikes this month, following data showing that while the US economy gained 339,000 jobs last month, pay growth slowed and the unemployment rate climbed.

The EPS catapulted from Rs 14.09 to Rs 32.30, over the last year and achieve year-on-year growth of 129 per cent.

At the pre-opening bell, the frontline index S&P BSE Sensex opened in green with a gain of 61.33 points or 0.10 per cent.

Shares of the company grew by more than 50 per cent in the last six months.